Human EPCAM knockout A-431 Cell Line

Description

Human EPCAM Knockout A-431 Cell Line is generated from human epidermoid carcinoma A-431 cells through CRISPR/Cas9-mediated disruption of the Epithelial Cell Adhesion Molecule (EPCAM) gene, a transmembrane glycoprotein critical for cell-cell adhesion and Wnt/β-catenin signaling. This knockout model exhibits impaired epithelial integrity and reduced proliferation while maintaining A-431 cells’ characteristic adherent growth with cobblestone morphology. The cell line serves as an essential tool for studying epithelial-mesenchymal transition (EMT), cancer stem cell biology, and targeted therapy resistance, particularly in research involving circulating tumor cells (CTCs) and antibody-based cancer therapies. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through genomic PCR, Sanger sequencing, and flow cytometry confirming loss of EPCAM surface expression. Rigorous quality control confirms the cell line is free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The Human EPCAM Knockout A-431 Cell Line is a valuable model for studying epithelial cell adhesion and cancer progression. This engineered system enables investigation of EPCAM’s roles in cell signaling, proliferation, and metastasis in squamous cell carcinoma. Researchers utilize this knockout line to examine disrupted cell-cell interactions and altered tumorigenic potential. The cell line provides a controlled platform for evaluating EPCAM-targeted therapies and developing novel treatments for epithelial-derived malignancies.